Edition:
India

Medifast Inc (MED.N)

MED.N on New York Stock Exchange

65.09USD
27 Mar 2020
Change (% chg)

$-4.48 (-6.44%)
Prev Close
$69.57
Open
$67.79
Day's High
$68.61
Day's Low
$64.81
Volume
49,071
Avg. Vol
88,029
52-wk High
$159.41
52-wk Low
$49.31

Latest Key Developments (Source: Significant Developments)

Medifast Sees Q1 Earnings Per Share Of $1.35 To $1.42
Thursday, 27 Feb 2020 

Feb 26 (Reuters) - Medifast Inc ::MEDIFAST, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.SEES Q1 EARNINGS PER SHARE $1.35 TO $1.42.SEES FY 2020 EARNINGS PER SHARE $6.25 TO $6.55.Q4 EARNINGS PER SHARE $1.66.SEES FY 2020 REVENUE $715 MILLION TO $745 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.07 -- REFINITIV IBES DATA.SEES Q1 REVENUE $166 MILLION TO $171 MILLION.Q4 REVENUE $170.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $161.7 MILLION.Q1 EARNINGS PER SHARE VIEW $1.61, REVENUE VIEW $175.6 MILLION -- REFINITIV IBES DATA.FY2020 EARNINGS PER SHARE VIEW $6.70, REVENUE VIEW $782.3 MILLION -- REFINITIV IBES DATA.  Full Article

Medifast Announces 51% Increase In Quarterly Dividend
Wednesday, 4 Dec 2019 

Dec 3 (Reuters) - Medifast Inc ::MEDIFAST, INC. ANNOUNCES 51 PERCENT INCREASE IN QUARTERLY DIVIDEND.SETS QUARTERLY CASH DIVIDEND OF $1.13PER SHARE.EXPECTS TO MAINTAIN A PROGRAM OF PAYING DIVIDENDS ON A QUARTERLY BASIS.  Full Article

Engaged Capital Reports 9.99% Stake In Medifast
Monday, 18 Nov 2019 

Nov 18 (Reuters) - Medifast Inc ::ENGAGED CAPITAL LLC REPORTS 9.99% STAKE IN MEDIFAST INC AS OF NOV 7, 2019 - SEC FILING.ENGAGED CAPITAL LLC - PURCHASED MEDIFAST'S SHARES BASED ON ’ BELIEF THAT MEDIFAST'S SHARES, WHEN PURCHASED, WERE UNDERVALUED.ENGAGED CAPITAL LLC-HAVE ENGAGED, INTEND TO CONTINUE TO ENGAGE, IN COMMUNICATIONS WITH MEDIFAST REGARDING OPPORTUNITIES TO MAXIMIZE SHAREHOLDER VALUE.  Full Article

Medifast Sees FY 2019 Earnings Per Share $5.80 To $5.90
Friday, 8 Nov 2019 

Nov 7 (Reuters) - Medifast Inc ::MEDIFAST, INC. ANNOUNCES THIRD QUARTER 2019 RESULTS.SEES FY 2019 EARNINGS PER SHARE $5.80 TO $5.90.SEES Q4 EARNINGS PER SHARE $1.03 TO $1.13.Q3 EARNINGS PER SHARE $1.32.SEES Q4 REVENUE $157 MILLION TO $167 MILLION.SEES FY 2019 REVENUE $700 MILLION TO $710 MILLION.Q3 REVENUE $190.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $195.2 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $1.34 -- REFINITIV IBES DATA.ANNOUNCES NEW 2.0 MILLION STOCK REPURCHASE AUTHORIZATION.UPDATES FULL YEAR OUTLOOK.Q4 EARNINGS PER SHARE VIEW $2.06, REVENUE VIEW $202.3 MILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $6.84, REVENUE VIEW $750.5 MILLION -- REFINITIV IBES DATA.  Full Article

Medifast Inc Reports Q1 Earnings Per Share $1.70
Thursday, 2 May 2019 

May 1 (Reuters) - Medifast Inc ::MEDIFAST, INC. ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.SEES FY 2019 EARNINGS PER SHARE $6.70 TO $6.90.SEES Q2 EARNINGS PER SHARE $1.67 TO $1.72.Q1 EARNINGS PER SHARE $1.70.SEES Q2 REVENUE $180 MILLION TO $185 MILLION.SEES FY 2019 REVENUE $720 MILLION TO $740 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.54 -- REFINITIV IBES DATA.Q1 REVENUE ROSE 68.2 PERCENT TO $165.9 MILLION.SAYS COMPANY RAISES FULL YEAR 2019 OUTLOOK.SAYS FOR Q1 OF 2019, REVENUE INCREASED 68.2% TO $165.9 MILLION FROM REVENUE OF $98.6 MILLION FOR Q1 OF 2018.  Full Article

Medifast, Inc. Completes $10 Million Stock Repurchase
Thursday, 15 Nov 2018 

Medifast Inc ::MEDIFAST, INC. COMPLETES $10 MILLION STOCK REPURCHASE.  Full Article

Medifast Reports Q3 EPS Of $1.14
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Medifast Inc ::MEDIFAST, INC. ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.SEES Q4 EARNINGS PER SHARE $1.15 TO $1.20.Q3 EARNINGS PER SHARE $1.14.SEES Q4 REVENUE $137.3 MILLION TO $142.3 MILLION.RAISES FY 2018 EARNINGS PER SHARE VIEW TO $4.45 TO $4.50.SEES FY 2018 REVENUE $492.5 MILLION TO $497.5 MILLION.Q3 REVENUE $139.2 MILLION VERSUS I/B/E/S VIEW $125.8 MILLION.Q3 EARNINGS PER SHARE VIEW $1.14 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.48, REVENUE VIEW $471.9 MILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $1.16, REVENUE VIEW $130.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article